Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Loa Loa (eye worm) | angiotensin-converting enzyme family protein | 0.0694 | 1 | 1 |
Schistosoma mansoni | alpha-galactosidase/alpha-n-acetylgalactosaminidase | 0.0079 | 0.0757 | 0.1575 |
Brugia malayi | Cyclin, N-terminal domain containing protein | 0.0042 | 0.0201 | 0.0022 |
Trichomonas vaginalis | cyclin A, putative | 0.0042 | 0.0201 | 0.2653 |
Schistosoma mansoni | alpha-galactosidase/alpha-n-acetylgalactosaminidase | 0.0079 | 0.0757 | 0.1575 |
Toxoplasma gondii | melibiase subfamily protein | 0.0079 | 0.0757 | 0.5 |
Trypanosoma cruzi | glutathionylspermidine synthase, putative | 0.0379 | 0.526 | 1 |
Trichomonas vaginalis | cyclins, putative | 0.0042 | 0.0201 | 0.2653 |
Trichomonas vaginalis | cyclins, putative | 0.0042 | 0.0201 | 0.2653 |
Leishmania major | trypanothione synthetase, putative | 0.0073 | 0.066 | 1 |
Schistosoma mansoni | beta-galactosidase | 0.0277 | 0.3732 | 1 |
Trypanosoma cruzi | trypanothione synthetase | 0.0073 | 0.066 | 0.0908 |
Schistosoma mansoni | alpha-galactosidase/alpha-n-acetylgalactosaminidase | 0.0079 | 0.0757 | 0.1575 |
Echinococcus granulosus | beta galactosidase | 0.0277 | 0.3732 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0277 | 0.3732 | 0.3618 |
Trichomonas vaginalis | cyclin B, putative | 0.0042 | 0.0201 | 0.2653 |
Schistosoma mansoni | alpha-galactosidase/alpha-n-acetylgalactosaminidase | 0.0079 | 0.0757 | 0.1575 |
Giardia lamblia | G2/mitotic-specific cyclin B | 0.0042 | 0.0201 | 0.5 |
Echinococcus granulosus | Alpha N acetylgalactosaminidase | 0.0079 | 0.0757 | 0.1575 |
Trypanosoma brucei | trypanothione synthetase | 0.0073 | 0.066 | 1 |
Brugia malayi | Melibiase family protein | 0.0079 | 0.0757 | 0.0589 |
Loa Loa (eye worm) | hypothetical protein | 0.0042 | 0.0201 | 0.0022 |
Trichomonas vaginalis | cyclins, putative | 0.0042 | 0.0201 | 0.2653 |
Plasmodium falciparum | conserved Plasmodium protein, unknown function | 0.0085 | 0.0839 | 0.5 |
Echinococcus multilocularis | Alpha N acetylgalactosaminidase | 0.0079 | 0.0757 | 0.1575 |
Onchocerca volvulus | 0.0042 | 0.0201 | 0.5 | |
Loa Loa (eye worm) | hypothetical protein | 0.0079 | 0.0757 | 0.0589 |
Trypanosoma brucei | trypanothione synthetase, putative | 0.0073 | 0.066 | 1 |
Trichomonas vaginalis | cyclin B, putative | 0.0042 | 0.0201 | 0.2653 |
Entamoeba histolytica | cyclin, putative | 0.0042 | 0.0201 | 0.5 |
Schistosoma mansoni | alpha-galactosidase/alpha-n-acetylgalactosaminidase | 0.0079 | 0.0757 | 0.1575 |
Echinococcus multilocularis | beta galactosidase | 0.0277 | 0.3732 | 1 |
Trichomonas vaginalis | cyclin B, putative | 0.0042 | 0.0201 | 0.2653 |
Trichomonas vaginalis | cyclin B, putative | 0.0042 | 0.0201 | 0.2653 |
Loa Loa (eye worm) | hypothetical protein | 0.0042 | 0.0201 | 0.0022 |
Brugia malayi | Cyclin, N-terminal domain containing protein | 0.0042 | 0.0201 | 0.0022 |
Trichomonas vaginalis | cyclins, putative | 0.0042 | 0.0201 | 0.2653 |
Trichomonas vaginalis | alpha-galactosidase/alpha-N-acetylgalactosaminidase, putative | 0.0079 | 0.0757 | 1 |
Plasmodium vivax | hypothetical protein, conserved | 0.0085 | 0.0839 | 0.5 |
Echinococcus multilocularis | Glycoside hydrolase, family 27 | 0.0079 | 0.0757 | 0.1575 |
Trypanosoma cruzi | trypanothione synthetase | 0.0073 | 0.066 | 0.0908 |
Schistosoma mansoni | alpha-galactosidase/alpha-n-acetylgalactosaminidase | 0.0079 | 0.0757 | 0.1575 |
Loa Loa (eye worm) | hypothetical protein | 0.0277 | 0.3732 | 0.3618 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
ED50 (functional) | = 35 mg kg-1 | Anti-tetrabenazine (TBZ) activity, ability to prevent TBZ-induced ptosis in mice | ChEMBL. | 6471069 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.